Physician profile
James H Mcquiston
NPI 1053302091
$12,564.37
in general payments reported to CMS, 2019-2025
13 companies · $50.89 in 2025
The $50.89 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $207 · 2021: $167 · 2022: $95.50 · 2023: $240 · 2024: $135 · 2025: $50.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,932.71 | 2019-2024 | |
| Ibsa Pharma INC. | $116.96 | 2019-2023 | Tirosint, Licart |
| Zimmer Biomet Holdings, INC. | $108.93 | 2023 | Ribfix Blu Advantage |
| Checkpoint Surgical, INC | $82.57 | 2021-2023 | Checkpoint Stimulators |
| Takeda Pharmaceuticals U.S.A., INC. | $67.69 | 2021-2022 | |
| Innocoll Pharmaceuticals Limited | $53.71 | 2022 | |
| Kls-Martin L.P. | $45.74 | 2021-2023 | |
| Integra Lifesciences Corporation | $44.14 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Organogenesis INC. | $30.16 | 2023 | Puraply |
| Acera Surgical, INC. | $27.28 | 2025 | Restrata Wound Matrix |
| Convatec INC. | $23.91 | 2023 | |
| Medtronic, INC. | $15.40 | 2023 | Pteye Parathyroid Detection System |
| Abbvie INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcquiston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.